Biotechnology

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

Celularity Inc. has secured a $12.2M cash injection by selling tax losses, a move set to accelerate its cutting-edge longevity and regenerative medicine pipeline.

Kincell Bio and RegCell partner to bring a groundbreaking, non-gene-edited Treg cell therapy for autoimmune diseases from the lab to clinical trials.

With two high-profile board appointments, Stellaromics signals its ambition to dominate the 3D spatial omics market with its advanced Pyxa™ platform.

A new partnership between GeminiBio and Tolemy Bio introduces aiMOS™, an AI-powered service designed to cut costs and boost consistency in cell therapy production.

With a new CEO and stunning clinical data, BOOST Pharma advances a potential game-changer for children with the rare genetic disorder Osteogenesis Imperfecta.

Aardvark Therapeutics is expanding its Phase 3 trial for a novel Prader-Willi Syndrome drug to include children as young as seven, targeting a key unmet need.

Ahead of its first Climate Week, Mumbai's food innovators and activists gather to debate a sustainable future, proving the fight for the planet begins on our plates.

Amid major restructuring and a strategic asset sale, Standard BioTools' upcoming annual results will reveal its progress toward profitability in a tough market.

Enanta Pharmaceuticals unveils promising data for EDP-978, an oral drug targeting the root cause of conditions like chronic hives, asthma, and eczema.

The advisory giant's acquisition of a Boston-based specialist signals a strategic push into the high-stakes, high-growth world of life sciences and biotech.

Israeli startup Protai is set to reveal promising preclinical data for its cancer drug, PRT-001, powered by its unique proteomics-aware AI platform.

A new partnership between South Korea's GCCL and Europe's Medicover MICS promises to streamline drug development by creating a seamless East-West axis.

Swiss pharma Santhera appoints Stifel as advisor, a strategic move to fuel the global rollout of its DMD drug AGAMREE amid a complex biotech funding market.

Belgian biotech Agomab Therapeutics secures $200 million in its Nasdaq debut, fueling its mission to develop therapies for debilitating fibrotic conditions.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.

A new 'zero-disruption' plate from TheWell Bioscience aims to solve key challenges in organoid research, promising more reliable data for drug discovery.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

A new initiative backed by the Japanese government aims to transform the nation's world-class scientific research into globally competitive biotech companies.